Liverpool is the stronger choice when a company needs specific infection, clinical, data, biomanufacturing or translational assets that it can actually access there. London is stronger when repeated access to a broader investor, adviser, corporate and senior-talent market is commercially decisive. Neither city is the right answer for every function, and a split model works only when responsibilities, travel and quality systems are designed deliberately.
- OverviewLiverpool is the stronger choice when a company needs specific infection, clinical, data, biomanufacturing or translational assets that it can actually access there.
- Start with the next two company milestonesA location should help deliver the next technical and commercial milestones.
- Liverpool's value comes from specific assetsThe Liverpool City Region Life Sciences Innovation Zone identifies activity across the Knowledge Quarter, Sci-Tech Daresbury, Maghull, Speke and St Helens.
- Clinical partnerships require a route into deliveryLiverpool has universities, specialist hospitals and health organisations, while London has a larger set of major hospitals and research institutions.
- Laboratory and manufacturing availability must be checked separatelyLaboratory space is not a single product.
Liverpool is the stronger choice when a company needs specific infection, clinical, data, biomanufacturing or translational assets that it can actually access there. London is stronger when repeated access to a broader investor, adviser, corporate and senior-talent market is commercially decisive. Neither city is the right answer for every function, and a split model works only when responsibilities, travel and quality systems are designed deliberately.
The company should compare named facilities, partners and roles rather than the prestige of each city. Research, trials, manufacturing and commercial leadership have different dependencies. The useful decision is where each dependency can be met with the least execution risk.
Start with the next two company milestones
A location should help deliver the next technical and commercial milestones. For an infection-technology company, that may be access to specialist models and validation. For a diagnostics business, it may be clinical samples and evidence. For a therapeutics company, it may be a development laboratory, trial sites and a manufacturing route. For a commercial healthtech company, it may be national customers and senior sales hires.
The UK Life Sciences Sector Plan describes life sciences as a network of UK clusters. That national view supports a function-led decision. It does not establish which city is cheaper or better for an individual company.
Management should write a two-year operating map with named requirements: laboratory specification, clinical specialty, patient group, manufacturing process, quality responsibility, target customers, investor type and next hires. A city receives weight only where it improves one of those requirements.
The broader guide to placing life-sciences functions across Oxford, Cambridge and London uses the same method. Liverpool belongs in the comparison when its specialist capabilities match the work.
Liverpool's value comes from specific assets
The Liverpool City Region Life Sciences Innovation Zone identifies activity across the Knowledge Quarter, Sci-Tech Daresbury, Maghull, Speke and St Helens. Its public material highlights infection research, specialist hospitals, data and computing, materials, laboratories and biomanufacturing.
Those descriptions should be converted into access questions. Which facility serves external companies? What work can it perform? What is operational now? What is planned? What does access cost? Who owns results and intellectual property? How long is the queue? A company should not base a location decision on an asset it cannot contract to use.
The Zone includes a mixture of existing institutions, approved support and proposed facilities. For example, the Combined Authority's published updates distinguish buildings already in use from projects expected to complete later. Every proposed location should therefore carry a delivery status and evidence date.
Liverpool is particularly credible when the company can name an institutional partner and a concrete programme of work. A broad claim that the city has health assets is not enough.
Clinical partnerships require a route into delivery
Liverpool has universities, specialist hospitals and health organisations, while London has a larger set of major hospitals and research institutions. The deciding factor is relevance to the protocol and the organisation's ability to support delivery.
The NIHR Study Support Service provides national support for planning and delivering health and care research. For medicines, the MHRA clinical-trial authorisation guidance sets out the regulatory application route. These national systems mean that headquarters location and trial location do not need to be the same.
A company should identify the sponsor, chief investigator, delivery sites, contracting path, data responsibilities and recruitment assumptions. It should ask whether proximity will be needed weekly or only at defined study points. The answer may justify a Liverpool clinical team without moving commercial leadership, or a London evidence team while trials run elsewhere.
Institutional collaboration is not automatic. Before signing property, management should confirm the named relationship and realistic start date.
Laboratory and manufacturing availability must be checked separately
Laboratory space is not a single product. Wet laboratories, containment environments, clean rooms, analytical facilities and ordinary offices have different requirements. A planned laboratory-enabled building is not available capacity, while a completed building may still lack the equipment or permissions a company needs.
Liverpool's case can be strong where existing specialist facilities and lower occupancy costs support longer runway. London may provide more flexible office and dry-lab options in several districts, but suitable wet-lab and grow-on space can be constrained and expensive. The article on where a London life-sciences company should locate should be used for the within-London choice.
Manufacturing requires another test. The company must decide whether to own production, use a contract development and manufacturing organisation, or work with an established regional cluster. Biomanufacturing, diagnostics production and medical-device assembly need different suppliers, people and quality systems.
The UKRI Gateway to Research can help trace publicly funded infrastructure and collaborations. It does not confirm commercial availability. Facility operators must provide current terms, capacity and quality status.
London can carry commercial functions without absorbing the company
London offers dense access to investors, specialist legal and regulatory advisers, multinational partners and senior commercial candidates. That can matter during a fundraise, licensing process or international business-development programme. It does not require the entire research and production organisation to be there.
A company can maintain a small London commercial base, use flexible meeting space or schedule regular access. The right level depends on actual frequency. Management should count target organisations, meetings and hires that benefit from proximity, then compare those benefits with property and salary costs.
Regulation is national. The MHRA is not a customer acquired by renting near it. Specialist advisers may be available across the UK or remotely. London earns its place when it improves repeated commercial work, not because it appears more credible on a pitch deck.
Corporate structure should also be interpreted carefully. Companies House records show registered offices, filings and charges, but a registered London address does not prove that research, employment or management moved there.
Talent and cost comparisons need identical definitions
Liverpool and London labour markets differ in size, pay, housing and occupational mix. Total graduate counts or broad life-sciences employment figures are not sufficient. A company should list the precise roles required over two years and test recruitment through current vacancies, local institutions and specialist recruiters.
Scarce roles may include quality assurance, regulatory affairs, clinical operations, biostatistics, process development and experienced commercial leadership. Some can be hired nationally. Others need daily access to a site or team. Hybrid work changes the calculation but does not remove laboratory or manufacturing presence.
Cost comparisons must include more than rent. Fit-out, service charges, business rates, travel, duplicated management, recruitment time and staff turnover all matter. A Liverpool laboratory with frequent London travel may still be cheaper. A split structure with weak coordination may not be.
Three company types produce different answers
An infection-research spinout may place research and translation in Liverpool when it has a contracted institutional relationship, use external manufacturing and maintain periodic London investor access. This concentrates technical work around the scarce capability.
A clinical-stage therapeutics company may run research in Liverpool, place clinical staff near relevant delivery sites and keep commercial or financing leadership in London. It needs one development plan and one quality system across locations.
A commercial medtech company may put product and evidence work close to Liverpool health partners while locating sales leadership near national customers. If its main constraint is NHS procurement rather than research, the Leeds investigation into turning NHS access into repeatable national sales is also relevant.
The choice should be reviewed when the company changes development stage. A research-led location can become less important after technology transfer, while manufacturing, sales or international partnerships become more important.
A split model needs clear ownership
Every site should have a defined purpose, team and accountable leader. Shared systems should cover documents, quality, data, budgets and decisions. Travel assumptions should be explicit, including who travels, how often and what happens when schedules fail.
The company should avoid token offices. A small site without decision authority or a coherent team can create cost without access. It should also avoid moving intellectual property or senior management merely to satisfy an assumed investor preference. Ask investors and customers directly what presence they require.
The best model is the smallest network of sites that gives the company reliable access to its scarce dependencies.
Limitations
Laboratory availability, rents, incentives and programme delivery change quickly. Liverpool City Region material includes existing assets, approved projects and forecasts, which must remain separate. London and Liverpool statistics often use different geographies, so headline comparisons can mislead.
Private collaboration terms, clinical timelines, manufacturing capacity and investor requirements are rarely public. Before publication, this draft needs current facility checks, specialist review and company examples based on verified operating locations. No programme target should be presented as delivered investment, jobs or commercial success.
Reporting by Shoreditch Talk




